The PI3K inhibitor alpelisib is currently available in the clinic in combination with fulvestrant for postmenopausal women with advanced or metastatic hormone receptor-positive, HER-2-negative, PIK3CA-mutated breast cancer [9]. Here, ERBB2 is linked to breast cancer.